OrbiMed, a US-based life sciences investment firm, has announced raising more than $4.3 billion in commitments for its latest private investment funds, which include its fifth Asia-focused healthcare vehicle OrbiMed Asia Partners V.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
